




ADVANCING EUROPE'S LEADERSHIP IN LIFE SCIENCE

Thursday 12 June 2025

from 9:30 to 17:00





As Europe strengthens its strategic autonomy and competitiveness, immunology and immunotherapy are shaping the future of its health and biotech. This conference connects the latest scientific breakthroughs in immunology with EU policy goals, offering input for the Competitiveness Compass, the European Life Science Strategy, the Biotech Act, and the next Framework Programme for Research and Innovation.

Immunology is central to some of today's most promising treatments and preventive approaches. From infections and cancer to autoimmune and chronic diseases, the immune system plays a vital

role. Yet despite major progress, Europe's efforts in immunology research, research and innovation remain too scattered. A more coordinated approach is needed to turn scientific advances into real-world health solutions through spin-offs, start-ups, biotechs, and solutions through engagement with industry and pharma.

This event brings together leaders from the InFLAMES Innovation Ecosystem and Marseille Immunology Biocluster as well as others establishing similar health clusters in Europe, industry partners, regulators, decision-makers, and patient advocates. With exciting keynotes and insightful panels, this is an opportunity to shape a strong, shared European vision, where immunology drives better health, innovation, and resilience for all.



contents

Editorial 3

Overview of InFLAMES 6

Overview of Marseille Immunology
Biocluster 7

Agenda 8 > 9

Speakers 10 > 12

Moderators 13 > 14

Panelists 15 > 21

Scientific coordinators 22 > 23

Partners 24 > 27

overview of InFLAMES



InFLAMES
Solution is in Immunity

The InFLAMES Research Flagship is a joint effort of the University of Turku and Åbo Akademi, Finland. This is an ambitious and dedicated top-level immunological R&D cluster that is part of the Research Council of Finland's Flagship Programme. InFLAMES seeks a deeper understanding of normal and mistargeted inflammatory reactions in both health and disease. Aberrant immune responses are major pathogenic events in a wide range of diseases, from autoimmune diseases to cancer.

InFLAMES comprises more than 50 research groups, encompassing individuals with diverse multidisciplinary backgrounds, and forms an extensive research and innovation ecosystem. Our goal is to generate new breakthrough discoveries in immunology and immunology-based diagnostics and drug development and transform them to the benefit of patients through extensive collaboration with biotech and pharmaceutical companies and the public sector.

overview of MIB



Marseille Immunology Biocluster (MIB) aims to strengthen France's healthcare influence. Led by Aix-Marseille University with 20+ partners (pharma industry, biotech, research entities, hospitals, tech transfer offices, regional authorities), it has a €96M budget under France 2030 programme to advance immunotherapy drug development.

Based in Marseille, with 40+ years of immunology research, MIB fosters cooperation among national, European, and international players shaping immunology's future. As a biocluster and innovation catalyst, MIB unites leading scientists, clinicians, and companies to accelerate new antibody-based therapies and push healthcare innovation.

Academics, hospital practitioners, industry, investors, students, and public bodies benefit from technology platforms, an immunology start-up studio, and innovation support for SMEs, focusing on oncology, infectious diseases, autoimmune, and inflammatory disorders.

This pragmatic approach to innovative treatments, novel diagnostics, and Medtech will position Marseille as a global immunology hub and enhance France's scientific standing internationally.

agenda

9:30

Opening

- Denis BERTIN, Vice-President of the A*Midex Foundation, in charge of MIB

9:45

Immunology: latest scientific breakthroughs & challenges ahead

- Sirpa JALKANEN, Professor in Immunology, InFLAMES, Finland (15 min)

The rise of immunology in society

- Daniel OLIVE, Professor in Immunology, Marseille Immunology Biocluster (MIB), France (15 min)

Translating immune regulations into patient treatments for tackling human diseases

- 10 min for Q&A

10:25

Coffee break

10:50

1st Panel – Innovative ecosystems as a driver to advance R&I in health

- Lidia AGUILERA MARTÍNEZ, Director of Innovation of Center CaixaResearch Institute, Spain
- Rita CARSETTI, Vice-President of The International Union of Immunological Societies (IUIS), France
- Carole MASURIER, CEO of Marseille Immunology Biocluster (MIB), France
- Cristina NICULESCU, Senior Specialist, Life Sciences and Health Division, European Investment Bank, Luxembourg
- Raivo UIBO, Professor of Immunology, University of Tartu, Representative of the ImmunoHUB initiative, Estonia

Moderator: ► Joe HETTINGER, Research Manager, InFLAMES, Finland

11:50

Introduction

Powering Immunology Innovation: Euro-Biolmaging Accelerates Discovery and Translation

- John ERIKSSON, Director General, Euro-Biolmaging, Finland

12:00 Networking Lunch

13:00 **Strengthening Europe's sovereignty & competitiveness through health and life science research**

Forward-looking video keynote on European health and R&I policies and upcoming channels of action

► Sandra GALLINA, Director-General of Directorate General for Health and Food Safety, European Commission, Belgium

13:30 **2nd Panel – Enhancing Europe's leadership & sovereignty in health innovation**

► Introductory video speech by **Ville NIINISTÖ**, Member of the European Parliament, Finland

► Dr Caroline AURICHE-BENICHO, European Medicines Agency (EMA), Chair of Rheumatology and Immunology Working Party, Iceland

► Carmen LAPLAZA SANTOS, Head of Unit for Health Innovations, Directorate General for Research and Innovation (RTD), European Commission, Belgium

► Hugh LAVERTY, Chief Scientific Officer, Innovative Health Initiative (IHI) Joint Undertaking, Belgium

► Anca TOMA, Executive Director of European Patient Forum EPF, Belgium

Moderator: ► Céline DAMON, amU, Head of Mission Europe for Research (amU, CNRS, Inserm, IRD), France

14:40

Conclusion

► Timo VEROMAA, Professor of Practice, InFLAMES, Finland

► Denis BERTIN, Vice-President of the A*Midex Foundation, in charge of MIB

15:00 Cocktail Event

17:00 End of the conference



Denis BERTIN

*Vice-President of the A*Midex Foundation, in charge of MIB, France*

After obtaining a PhD in materials science in 1997 from the University of Montpellier, France, he joined Arkema as a research and development engineer until 2000. He then joined Aix-Marseille University to develop a research group on polymer sciences at the Faculty in Sciences and was recruited as a Professor in 2002 within the Chemistry, Biology and Free Radicals research unit. He has worked on nanostructured organic materials for a wide range of applications (health, environment, energy, sport, etc.). In 2006, he became Vice-President for Research at Aix-Marseille University. After fourteen years in the Faculty

of Science, he was assigned to the Faculty of Sports Science and the Institute of Movement Sciences (Aix-Marseille University and CNRS) to develop new areas of innovation and sports science. He is coordinator of the Fast Spor'In cluster, which focuses on innovation in sport and technology, and set up the Hipe Human Lab research support unit in 2023, which he heads up and which is involved in the 2024 Olympic and Paralympic Games in Paris and the 2028 Games in Los Angeles. Since 2018, he is President of IMéRA, the Institute for Advanced Studies in Aix-Marseille. Vice-president of research at Aix-Marseille University until 2015, he is now deputy vice-president in charge of the AMIDEX university foundation, dedicated to the excellence initiative programme.



Sandra GALLINA

Director-General of Directorate General for Health and Food Safety, European Commission, Belgium

Sandra Gallina is Director-General of Directorate General for Health and Food Safety (DG SANTE) at the European Commission. Sandra Gallina joined the European Commission in 1988. Gallina is Director-General for DG SANTE. Before joining DG SANTE, between 2018 and 2020 she was Deputy Director General for TRADE. Between 2014 and 2018 she was Director for DG TRADE Directorate D “Sustainable Development; Economic Partnership Agreements – African, Caribbean and Pacific; Agri-food and Fisheries”. Sandra Gallina was also the EU chief negotiator for the EU-MERCOSUR Free Trade Agreement. Between 2001 and 2009 she was the EU Lead Negotiator for Non-Agricultural Market Access in the WTO Doha Round and in that capacity, she defined and presented EU policy for the Doha Development Agenda on non-agricultural market access negotiations. Before joining DG TRADE, she worked in the Directorate General for Taxation and Customs Union (DG TAXUD) at the end of the 1990s.



Timo VEROMAA

Professor of Practice, InFLAMES, Finland

Timo Veromaa is a physician-scientist and biopharma executive with over 30 years of industry experience in large and small cap companies in the US and Europe. He helps scientists build and develop business skills and foster industry-academia partnerships for innovation. He is especially excited about the significant opportunity for ground-breaking medical innovation in combining health registry, biobank, and genome data. FINBB is a one-stop access point to nationwide biobank data and electronic health records, and he served as its first Chairman. Timo is also Chairman of the Board of Herantis Pharma Plc, a public, innovative clinical-stage drug development company

working on gene therapy and biologics, and Chairman Emeritus of Finnish Bioindustries, an industry association he served for 9 years. He has served as the Executive Chairman of Domainex, Ltd., a fast-growing private drug discovery service company in Cambridge, UK.

Moreover, as President and CEO of Biotie Therapies Corp., aided by a magnificent team, he transformed this therapeutics group into a NASDAQ US listed company with a marketed product and late-stage clinical pipeline in neurodegenerative diseases.



John ERIKSSON

Director General, Euro-Biolmaging, Finland

Prof. John E. Eriksson is the Director General of Euro-Biolmaging ERIC, the European Research Infrastructure for biological and biomedical imaging. He has played a central role in the creation and growth of Euro-Biolmaging and brings decades of leadership experience in imaging technologies and research infrastructures. Prof. Eriksson is a strong advocate for open access to cutting-edge imaging services and the role of research infrastructures in driving innovation, collaboration, and translation across disciplines.



Céline DAMON,

amU, Head of Mission Europe for Research (amU, CNRS, Inserm, IRD), France

Graduate of Institute of Political Studies and holder of a Master's Degree in European Studies from the Institute of European Studies in Brussels, Céline Damon has more than 20 years of expertise in European programmes. After an experience in Brussels, she created and led the Aix-Marseille University European

Operational Support Unit in charge of the EU's framework programmes. Under her leadership, amU has greatly improved its participation in the EU research program, ranking 3rd in French universities in terms of participation in Horizon 2020. Having led the European Operational Support Unit to maturity, she became the Director of the Mission Europe for Research in 2024, the unique joint European pre-award and post-award Office in France grouping more than 20 agents, dedicated to support every academics from amU, CNRS, Inserm and IRD, in Aix-Marseille in every steps of their R&I European projects.

Céline Damon has strong expertise in lobbying, awareness -raising, detection, proposal writing & post-award management on European research, and innovation programs; networking at national and European levels.



Joe HETTINGER

*Research Manager, InFLAMES,
Finland*

Joe Hettinger holds a PhD from Queen's University in Canada, originally involved in psychiatric genetics and autism spectrum disorders. His background is in healthcare, working at the Cyprus Institute of Neurology and Genetics and the biotechnology spin-off NIPD Genetics. He was involved in the development and commercialization of genetic diagnostic services and IVD medical devices, with experience in industry funding and management, regulatory affairs, and stakeholder engagement in start-ups.

Dr. Hettinger was also involved in the establishment of CYENS and as Partnerships Manager was responsible for identifying and building relationships between the Centre of Excellence and commercial and non-commercial organizations in Europe and abroad to manage innovation and knowledge exchange activities. For the past four years, as a Research Manager of the InFLAMES Flagship in Finland, he has supported the flagship's over 400 researchers in obtaining research funding and fostering industry engagement, with the main focus to drive immunology findings from the bench-to-the-bedside.

panelists

Lidia AGUILERA MARTÍNEZ

*Director of Innovation of Center
CaixaResearch Institute, Spain*

Dr. Aguilera is currently the Director of Innovation at CaixaResearch Institute, Spain's first research centre specializing in immunology. Dr. Aguilera is a seasoned technology transfer professional with a PhD in nanotechnology and over 20 years of international experience across public and private research. After developing her scientific career at leading research centers in Europe, she expanded her expertise into innovation and R&D evaluation, contributing regularly to national



and international initiatives. She has previously led knowledge transfer and business development at several universities and a consulting firm, where she managed high-level industry collaborations and multidisciplinary teams. Her work spans biotechnology, medical devices, human sciences, new materials, and more—covering innovation strategy design, IP portfolio analysis, licensing negotiations, and global tech scouting.

Caroline AURICHE- BENICHO

*European Medicines Agency (EMA),
Chair of Rheumatology and
Immunology Working Party, Iceland*

Caroline Auriche is by training a Pharmacist and a Biologist, with an Upper Degree in cell and molecular biology and a recent Master 2 in gene therapy, cell therapy and immunotherapy. Caroline has almost 30 years of experience in the clinical assessment of drugs in the French



and Icelandic Medicines Agency, and a 15-year experience as member of the Scientific Advice Working Party of the European Medicines Agency (EMA) where she performs monthly critical analyses of clinical development plans and clinical trial designs of all development phases, with a focus on rare diseases and autoimmune diseases. Since 2023, she is the Chairman of the Rheumatology-Immunology Working Party in charge of the drafting of clinical development Guidelines in the field at the EMA.



Rita CARSETTI

Vice-President of The International Union of Immunological Societies (IUIS), France

Rita Carsetti trained in Medicine and OB-GYN at La Sapienza University and then pursued research at M.D. Anderson (Houston) and Max Planck Institute (Freiburg), where she led the flow cytometry core and worked

with Nobel Laureate Georges Köhler and later with Michael Reth, and Thomas Boehm. After 13 years in Germany, she joined Bambino Gesù Children's Hospital (Rome), shifting from murine to human B cells for more patient-focused research. As head of the Diagnostic Immunology Unit, she studies B cell responses in aging, immunodeficiency, infection, transplantation, and vaccination. Her recent work on SARS-CoV-2 and mRNA vaccines highlights memory B cells and mucosal immunity in neonates born to infected mothers. Bridging basic and clinical immunology, her research informs immune protection and disease. Dr. Carsetti leads the B-cell Research Unit at Bambino Gesù, is Adjunct Professor of Immunology at the Medical University of Vienna, and president-elect of the International Union of Immunological Societies.

**Carmen
LAPLAZA
SANTOS**



*Head of Unit for Health Innovations,
Directorate General for Research
and Innovation (RTD), European
Commission, Belgium*

Carmen Laplaza Santos works for the European Commission, where she is currently the Head of the Health Innovations and Ecosystems Unit within the Directorate-General for Research and Innovation. Prior to this role, she was Deputy Head of the Innovative and Personalised Medicine Unit within the same Directorate-General.

Carmen has also worked for the Directorate-General for Communications Networks, Content and Technology, where she was Deputy Head of the E-Health, Wellbeing and Ageing

Unit and she was also responsible for the budget sector, dealing mainly with the financial implementation of the Seventh Framework Programme (FP7) and the Horizon 2020 research framework programmes. Before joining the European Commission in 2008, she held senior roles in financial and strategic departments of different sectors, such as retail, advertising, and banking. Carmen studied at the University of Navarra in Spain and in 1994 she obtained a degree in economics.



Hugh LAVERTY

*Chief Scientific Officer, Innovative
Health Initiative (IHI) Joint
Undertaking, Belgium*

Hugh Lavery is Head of Scientific Operations at IHI, where he leads a team of scientific and financial officers responsible for the operational activities of the organization. He is responsible for the overall planning, management

and monitoring of calls for proposals, and evaluations leading to projects/grant agreements, as well as management of the projects themselves. He held the same position in IMI2 between 2015 and 2021. He joined IMI as a Senior Scientific Project Manager in 2011, managing specific projects and overseeing IMI's engagement with small and medium-sized enterprises (SMEs).

Before joining IMI, Hugh worked as Industry Programme Manager at the Centre for Drug Safety Sciences at the University of Liverpool, UK. He also has extensive experience in the Biotech sector, having spent nearly 10 years working in an SME identifying and developing recombinant proteins as novel therapeutics for the prevention of dermal scarring. Trained as a molecular biologist, he holds a PhD in gene cloning and developmental biology, with an interest in a wide range of scientific areas and research questions.



**Carole
MASURIER**

*CEO of Marseille Immunology
Biocluster (MIB), France*

Carole Masurier, MBA, MAE, PhD, HDR, is the CEO of the Marseille Immunology Biocluster (MIB). With a strong background in the biotech and pharmaceutical sectors, she brings extensive leadership experience to this role. Prior to joining MIB, Dr. Masurier has held key roles in both the biotech industry and academic research, notably at Genethon and as CEO of GenoSafe for the past seven years. Her expertise lies in strategic development, innovation management, securing public funding, and fostering collaborative ecosystems. Her academic credentials include a

PhD in Biology, an HDR (Accreditation to Supervise Research), an MBA, and an Executive Master in Business Administration and Management, both earned as valedictorian. She is recognized for her ability to bridge science, business, and innovation in highly collaborative environments. At MIB, she is responsible for and developing the cluster as a European hub of excellence in immunology, supporting the growth of start-ups and accelerating clinical trials. Under her leadership, MIB is poised for significant growth and impact in the global scientific community.

Cristina NICULESCU

Senior Specialist, Life Sciences and Health Division, European Investment Bank, Luxembourg

Cristina Niculescu has been working as a Senior Life Science Specialist at the European Investment Bank (EIB) since July 2016. In this role, she has overseen investments, particularly venture debt, in a portfolio of innovative companies throughout Europe

including BioNTech, Anocca, and Indivumed (exited in 2023).

She has also played a key role in establishing impact funds such as the AMR fund and framework loans like Afreximbank.

With twenty years of experience in research and development, Cristina brings a wealth of knowledge in immune-oncology, therapeutic vaccines for infectious diseases (ID), and ID-related

cancers. Prior to joining the EIB, she made significant contributions to the portfolio of Transgene, SA, a biopharmaceutical company affiliated with Institut Mérieux. There, she successfully completed various projects in pre-IND and early clinical development (Phase I/Ib), focusing on chronic HBV and skin cancers across Europe, Canada, China, and Australia. She also played a key role in the

company's in-licensing and business development activities. Between 2006 and 2009, Cristina conducted research projects in developmental biology of rare diseases at the Institut de Génétique, Biologie Moléculaire et Cellulaire (IGBMC), Strasbourg, France. She earned a PhD. in Pharmacology and Toxicology from the RWTH, Aachen Germany and an MBA in Financing Innovation at HEC, Paris France and Babson College, Boston, USA.



VILLE NIINISTÖ

Member of the European Parliament, Finland

Ville Niinistö is a Member of the European Parliament. He is the Greens/EFA group's coordinator in the Committee on Industry, Research and Energy and a member of the Committee on Environment. He is also the Chair of the Delegation to the EU-Russia Parliamentary Cooperation Committee and a substitute

member of the Delegation on relations with the NATO Parliamentary Assembly. Niinistö served as Finland's Minister of the Environment from 2011 to 2014. He is a former member of the Finnish parliament, former party leader of the Greens in Finland, and a current member of the city council of Turku. Niinistö holds a master's degree in political science from the University of Turku. Before being elected to parliament in 2007, he worked as a doctorate student in political history (Finnish foreign policy) at the University of Turku in Finland.



Anca TOMA

Executive Director of European Patient Forum (EPF), Belgium

Anca Toma joined European Patient Forum as Executive Director in March 2022.

Her career started in the Romanian EU accession negotiations team,

continued as a consultant in a public affairs and communications agency in Brussels, followed by ten years in Smoke Free Partnership, a European coalition of NGOs working to advance tobacco control for cancer and NCD prevention.

Anca has over 15 years of experience in European health policy working in policy advocacy, strategic communications, developing and coordinating successful pan-European advocacy campaigns, and leading her team and organisation. Anca is a political science graduate of the University of Bucharest and holds a Masters in European politics and administration from the College of Europe.



Raivo UIBO

*Professor of Immunology,
University of Tartu, Representative
of the ImmunoHUB initiative, Estonia*

Raivo Uibo is Professor of Immunology, Head of the

Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu. He is a member of the Estonian Academy of Sciences.

R. Uibo graduated from the University of Tartu with an MD degree and obtained a PhD degree in Internal Medicine in 1978. In 1990, he received a DMSci degree from the University of Tampere. He had postgraduate stays at the University of Tampere (immunopathology), Monash University (immunology), and Brussels University (IRIBHN, molecular medicine).

Later, he worked as a visiting scientist at the University of Turku in 2005, at Lund University in 2008, and at University College London in 2018. He has worked on several local and international research grants, including participation in EU F6, F7, and H2020 projects and in a CoE project for Newly Associated States in 2001–2003 where he was project chair. He has about approximately 250 scientific publications and 19 PhD degrees were defended under his supervision.

scientific coordinators

**Sirpa
JALKANEN**



*Professor in Immunology, InFLAMES,
Finland*

Academician Sirpa Jalkanen, MD, PhD, is the Director of the national Flagship InFLAMES in Finland. She has published over 400 peer-reviewed papers and holds more than 10 patents in the fields of inflammation and cancer, some of which are serving as targets for drug development.

She is a member of EMBO and Academia Europaea, and has received numerous awards and honors, including the Datta Medal (from FEBS), major medical awards such as the Anders Jahre and Äyräpää Prizes, as well as innovation awards like the 2nd Prize in the European Women Innovators competition and the Finnish Pharma Industry Prize. She was also a finalist for the European Inventor Award in 2024. Professor Jalkanen serves as a member, vice chair, or chair of the boards of three major Finnish foundations supporting research, as well as of the Association of Finnish Foundations. In addition, she is a co-founder of two publicly listed biotech companies.



Daniel OLIVE

*Professor in Immunology,
Marseille Immunology Biocluster
(MIB), France*

After training in Internal Medicine, Daniel Olive became Professor of Immunology at Aix-Marseille-University and Institut Paoli Calmettes, leading the “Immunity and Cancer” INSERM UMR1068 team at Marseille Cancer Research Center. He heads the first IBISA Cancer Immunomonitoring Platform. A pioneer in co-signaling since 1990, his work focuses on tumor immunology, innate immunity, and co-signaling molecules. Major breakthroughs include: identifying the CD28 and ICOS pathways; demonstrating BTN3A1/CD277 as a key Vg9Vd2 inducer; recognizing AML by Vg9Vd2; uncovering BTLA and HVEM’s role

in immune regulation and as escape mechanisms in melanoma and lymphoma; revealing NK cell impairment in AML and breast cancer tumor beds; leading the first clinical anti-KIR mAb trial in AML; showing pDC targeting by HCV; and deciphering ICOS-ICOSL regulation of Tregs in lymphomas and CTCL. He is an expert on innate cells in the tumor microenvironment and actively translates discoveries to biotech, co-founding Imcheck Therapeutics, Emergence Therapeutics, Alderaan Biotechnology, and out-licensing patents (ICOS to GSK, anti-CD28 to Ose Immunotherapeutics and Asahi Kasei, and CD277 to Imcheck Therapeutics in clinical trials).



Aix-Marseille University (amU) is the largest French-speaking university, with 80,000 students and nearly 8,000 staff members. It includes the Institute for Cancer and Immunology, which brings together more than 120 teams and 800 staff across 7 research units. Overall, the university comprises 122 research units and 18 multidisciplinary graduate schools. The university was founded on January 1, 2012, by the merger of the three previously existing universities in Aix-en-Provence and Marseille. As a comprehensive and research-intensive university, amU conducts its research activities in the Metropolis of Aix-Marseille with the largest French research organisations (CNRS, CEA, IFSTTAR, Inserm, INRAE, and IRD). amU is one of the three first French universities granted as 'Excellence Initiative' in 2016 under the French "Investing for the future" programme (PIA). amU is ranked the second French university in terms of participation under the European framework programme for research under the Horizon 2020.



Euro-BioImaging is the European Research Infrastructure for biological and biomedical imaging, providing open access to more than 120 cutting-edge technologies across 248 facilities in 18 countries and EMBL.

It empowers academic and industrial researchers through expert services, image data management, and Open Science practices. By supporting innovation, interdisciplinary collaboration, and AI-driven analysis, Euro-BioImaging empowers breakthroughs from life sciences to digital health, while bridging research and industry to address global challenges.



UNIVERSITY OF TURKU

The University of Turku is a multidisciplinary, international, research-intensive, entrepreneurial university that is ranked among the top 1% of universities in the world.

It has eight research faculties: Humanities, Law, Education, Social Sciences, Turku School of Economics, Science, Technology, and Medicine, serving over 22,000 students and 3,300 staff members. Each year, the University of Turku hosts 2,300 international students from over 100 countries. The university maintains comprehensive Open Science, equality, ethics, and IPR policies and has received the European Commission's HR Excellence in Research award for implementation of the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers (Charter & Code). Moreover, the University of Turku has earned (3/2022) ACEEU International Accreditation as Recognition for Entrepreneurial Activities and Societal Impact, further reflecting the university's aim to create new knowledge and solutions for global challenges.



Åbo Akademi University (ÅAU) is the only exclusively Swedish language multi-faculty, internationally acknowledged research university providing higher education in Swedish in Finland. ÅAU has 15 doctoral programs in four faculties and several doctoral networks with 4-year, funded doctoral positions. Through its funded doctoral positions, ÅAU intends to make a concrete investment in high-quality doctoral education. ÅAU has 1,200 employees, of which 700 are working in education and research as well as 5,700 undergraduate students and 900 postgraduate students. ÅAU annually attracts more than 1,000 international students representing over 80 countries. ÅAU is recognized for its contribution to Solutions for Health, a joint research community together with the University of Turku, where research is multifaceted and interdisciplinary. From bioengineering to individualized therapies, psychological treatments, and robotic and AI healthcare solutions.

Handwriting practice lines consisting of 28 horizontal dotted lines.

Handwriting practice lines consisting of 20 horizontal dotted lines.



InFLAMES
Solution is in Immunity



Marseille
Immunology
Biocluster



UNIVERSITY
OF TURKU

amU
Aix Marseille Université

Åbo Akademi
University